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Abstract 46 
Data monitoring committees (DMCs) play a crucial role in the conduct of clinical trials to ensure 47 
the safety of study participants and to maintain a trial’s scientific integrity.  Generally accepted 48 
standards exist for DMC composition and operational conduct.  However, some relevant issues 49 
are not specifically addressed in current guidance documents, resulting in uncertainties regarding 50 
optimal approaches for communication between the DMC, steering committee, and sponsors, 51 
release of information, and liability protection for DMC members.  The Heart Failure 52 
Association (HFA) of the European Society of Cardiology (ESC), in collaboration with the 53 
Clinical Trials Unit of the European Heart Agency (EHA) of the ESC convened a meeting of 54 
international experts in DMCs for cardiovascular and cardiometabolic clinical trials to identify 55 
specific issues and develop steps to resolve challenges faced by DMCs. The main 56 
recommendations from the meeting relate to methodological consistency, independence, 57 
managing conflicts of interest, liability protection, and training of future DMC members.  This 58 
paper summarizes the key outcomes from this expert meeting, and describes the core set of 59 
activities that might be further developed and ultimately implemented by the ESC, HFA, and 60 
other interested ESC constituent bodies.  The HFA will continue to work with stakeholders in 61 
cardiovascular and cardiometabolic clinical research to promote these goals.   62 
 63 
Keywords:  clinical trials; data monitoring committees; data safety monitoring board; clinical 64 
trials as topic; cardiovascular diseases 65 
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INTRODUCTION 67 
 Data monitoring committees (DMCs) play a key role in the conduct of clinical trials.  68 
Their primary obligation is to ensure the safety of study participants while maintaining trial 69 
integrity.1  DMCs achieve these functions primarily through reviewing interim safety and 70 
efficacy data, which assess the likelihood of harm, efficacy, or futility and the balance of risk 71 
versus benefit, supplemented by existing knowledge and evidence external to the trial.  Pre-72 
defined statistical guidelines serve as a construct for decision-making, but DMCs may 73 
legitimately take action outside of these guidelines if the data are sufficiently compelling to do 74 
so. 75 
 DMCs are required by regulatory authorities for some, but not all studies.  Studies 76 
requiring a DMC are typically large, later phase (usually phase 3), randomized, multi-center 77 
trials that evaluate mortality or major morbidity outcomes.  Early phase or feasibility trials may 78 
also warrant a DMC if there is a potential for significant risks to subjects, or for complex, novel 79 
therapies where little may be known about the array of potential responses to the study agent.2;3  80 
DMCs assembled for earlier phase studies may be responsible for multiple studies and often 81 
continue through phase 3, or DMCs may be set up program-wide for more than one study in 82 
parallel, to achieve continuity and maximize the DMC’s experience with the therapy, which may 83 
be particularly important for novel regimens.   84 
 Generally accepted standards exist for DMC composition and operational conduct.2-5  85 
Often, some relevant issues are not specifically addressed in current guidance documents or 86 
DMC charters, such as the communication structure between the DMC, steering committee, and 87 
sponsors (specifically when DMC recommendations are not followed), release of information, 88 
and liability protection for DMC members.   89 
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 The Heart Failure Association (HFA) of the European Society of Cardiology (ESC), in 90 
collaboration with the Clinical Trials Unit of the European Heart Agency (EHA) within ESC 91 
recognized that independent, qualified, and experienced DMCs are an important vehicle for 92 
protecting the integrity of cardiovascular clinical trials, and these areas of uncertainty warranted 93 
discussion in an open forum.  A meeting of international experts in DMCs for cardiovascular and 94 
cardiometabolic clinical trials was organized in 2015 and supported by the HFA to identify 95 
specific issues and advise steps to resolve challenges faced by DMCs.  These societies 96 
acknowledge that identifying experienced individuals without significant conflicts of interest (i.e. 97 
potential for themselves or close personal connections to substantially benefit financially, 98 
professionally, or intellectually from the trial results) who are willing to participate on a DMC 99 
can be challenging.  Finally, formal approaches are lacking to cultivate a greater number of 100 
appropriately experienced individuals to serve on DMCs, and the participants sought to use this 101 
forum to explore training approaches for future DMC leaders and members.  This paper 102 
summarizes the key outcomes from this expert meeting. 103 
 104 
OVERVIEW OF THE ROLE OF THE DATA MONITORING COMMITTEE 105 
 DMCs are primarily in place to ensure that patient safety is not compromised in an 106 
ongoing trial, and these committees consider safety from several perspectives.  The most 107 
straightforward aspect is monitoring for emergence of serious or unexpected adverse events or 108 
toxicities and stopping a trial for evidence of harm.  For less severe safety signals, the DMC may 109 
convey relevant information to the steering committee or study sponsor that triggers a protocol 110 
amendment, increased surveillance, or additional training in studies that involve devices or 111 
procedures.  More complex considerations include stopping a trial early when there is 112 
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overwhelming evidence (i.e., beyond a reasonable doubt and statistically supported) of a 113 
mortality benefit, such that the trial can be brought to rapid completion to expedite the 114 
availability of an effective therapy to the broader patient population, and to protect 115 
placebo/control group and future patients from the risk of delayed access to treatment.  However, 116 
stopping early for benefit must be balanced against the risk of stopping too early on a “random 117 
high” such that the results, once released, are misleading, uninterpretable, or insufficiently 118 
convincing to obtain regulatory approval/marketing authorization, change clinical practice, or 119 
satisfy payers.6-11  A trial stopped inappropriately early also faces the ethical problem of wasting 120 
the contributions of study participants if the data are ultimately not informative.  DMCs are also 121 
charged with protecting subjects from assuming unnecessary risks of clinical trial participation 122 
when a study appears to be futile (i.e., no chance for participating patients to benefit).  Both 123 
industry and publicly funded trials may consider futility analysis to avoid wasting limited 124 
resources.  However, declaring futility also assumes risks, such as the potential for missing a 125 
delayed treatment effect, an effect on important secondary endpoints, or definitive evidence of 126 
neutrality which is important information especially for marketed products (Table 1). 127 
 DMCs may also provide recommendations for clinical trial operations to the extent that it 128 
impacts the DMCs ability to effectively monitor safety (e.g., timeliness of adjudication and 129 
obtaining source documentation, interim data, or event reporting) or if study integrity is at risk 130 
(e.g., minimizing missing data or dropouts, avoiding excessive regional variation in application 131 
of guideline-directed medical therapy).  DMCs are becoming more pro-active in recognizing 132 
problems that may impact study integrity as they are occurring in real-time.  For example, the 133 
DMC in the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone 134 
Antagonist Trial [TOPCAT] reviewed characteristics and event rates of enrolled patients and 135 
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made recommendations for subsequent enrollment as well as substudies to assess heart failure 136 
severity during the trial12.  DMCs can also be responsible for other functions, such as 137 
recommending protocol adjustments for sample size or dose selection based on accrued data for 138 
studies with adaptive designs (i.e., where the study design can be modified at planned interim 139 
analyses, controlling for type I error13;14) according to a valid, pre-specified plan.15 140 
 The DMC charter should include the responsibilities of the DMC, its structure, format for 141 
reports, statistical guidelines for recommending trial termination, contractual and 142 
indemnification information, processes for conducting open meetings (may include sponsor, 143 
steering committee, study personnel to facilitate sharing information relevant to study progress 144 
but interim data are not discussed) and closed sessions (limited to DMC members and the data 145 
center statistician since interim data are discussed), procedures to ensure confidentiality, and 146 
communication pathways.4;16;17  Although charter templates have been proposed,16 none have 147 
been uniformly adopted. 148 
 149 
IMPORTANCE OF AN INDEPENDENT DATA MONITORING COMMITTEE 150 
 Independence is an attribute that is necessary for the DMC to perform its intended 151 
function.  The DMC must be free to evaluate the data, request analyses, and make 152 
recommendations without influence (or the perception of influence) from the sponsor, steering 153 
committee, investigators, or other parties involved in the trial.  DMC members should have no 154 
other involvement with the trial and maintain strict confidentiality with regards to interim data.  155 
Relevant financial or intellectual conflicts of interest should be avoided or mitigated.   156 
 157 
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Conflicts of Interest 158 
 Independence as it relates to a DMC can be complex.  Steering committee members may 159 
propose potential candidates to serve on a DMC to the study sponsor or at a minimum, provide 160 
advice to the sponsor regarding the proposed DMC membership.  Sponsors may have sole 161 
responsibility for choosing DMC members for trials without a steering committee (e.g., some 162 
phase 2 trials).  It is pertinent to note that the term “sponsor” is a single term but it can describe 163 
different entities or roles, depending on the study.  The sponsor generally maintains final 164 
responsibility for the study, and may be the “owner” of the data and results, but the sponsor is 165 
not necessarily the funding source, and the funding source is not necessarily a commercial 166 
company.  It is important to note that DMCs are in place to protect patient safety and the overall 167 
integrity of the trial, which is in the interest of all stakeholders (i.e., patients, investigators, 168 
sponsors, clinicians).  However, remuneration for DMC services could be perceived as a conflict.  169 
Serving on a DMC requires considerable expertise and time commitment; thus, reasonable 170 
compensation commensurate with the time commitment and work involved is justified and in 171 
accordance with regulatory guidance,3 although no compensation standards are available.  172 
Involving highly knowledgeable individuals on a DMC is desirable, but these individuals may be 173 
more likely than non-experts to have conflicts that need to be managed.18  Although some 174 
conflicts may exist, DMC members should not have relationships that would result in significant 175 
financial, academic, intellectual, career, professional advancement, or other gains for themselves, 176 
their family members, or other close personal relationships based on the trial outcome.17  177 
Potential conflicts should be initially disclosed, and comprehensive reporting at routine intervals 178 
(i.e. every 6 to 12 months) should occur throughout the study.  Using contract or academic 179 
research organizations, professional organizations such as the HFA, or other third parties 180 
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independent of the sponsor to recommend or select DMC members and handle contracts and 181 
payments to DMC members has been proposed as a method to manage conflicts.  The structure 182 
of the contractual relationship should be transparently provided in legal documents and the 183 
“independence” of the third party should also be clearly described.  This approach has not yet 184 
been systematically implemented,4;17 and whether it would promote more efficient management 185 
of potential conflicts or create reporting inefficiencies remains to be determined. 186 
 187 
Liability 188 
 The issue of liability has been raised as a theoretical concern among DMC members.17-20  189 
The lay public and legal personnel are unlikely to appreciate the nuances of interpreting 190 
fluctuations in interim data, and they may fail to understand how early data may be misleading.19 191 
In the context of a litigious society, DMC members may be appropriately concerned that 192 
uninformed misinterpretations of safety data could expose them to legal action.20  Although 193 
actual cases have not yet been reported, many DMC members are concerned about potential 194 
legal action taken by patients who feel they have been harmed by participation in a study (and 195 
not adequately protected by the DMC), patients enrolled in placebo or standard therapy arms 196 
when the therapy tested is ultimately shown to be advantageous (i.e. holding DMC members 197 
liable for recommending that a study continue), or investors (e.g., either for allowing a study that 198 
was negative to continue or for not stopping a positive study earlier).  Sponsors may not provide 199 
indemnification of DMC members, a factor which may be a disincentive to DMC participation or 200 
unduly influence DMC decision-making.20  Several authors have called for indemnification of 201 
DMC members by the study sponsor, which should include support to cover legal counsel for the 202 
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DMC member independent from the sponsor’s legal counsel to avoid legal conflicts of 203 
interest.4;19;20 204 
 205 
Communication with Steering Committee and Sponsor 206 
 Processes for communication should be clearly specified in the DMC charter.  207 
Opportunities for inadvertent, informal communication between the DMC and other parties 208 
involved in the trial should be minimized; for instance, the DMC should avoid sponsor 209 
hospitality or advisory boards.  Interactions among these groups should be conducted under a 210 
principle of maintaining confidentiality of interim results,21 since release of interim data could 211 
bias investigators, study personnel, potential study enrollees, and the general public, and damage 212 
the integrity of the trial (e.g., Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of 213 
Glycemia in Diabetes [RECORD], Simvastatin and Ezetimibe in Aortic Stenosis [SEAS]).22;23  214 
The steering committee or sponsor may discuss blinded data with the DMC when appropriate to 215 
inform them about the overall study progress, status of endpoint adjudication, or adverse event 216 
reporting.24  In the context of adaptive designs, a limited group from the sponsor may interact 217 
with the DMC and have access to unblinded data, but beyond this purpose the authors strongly 218 
view that unblinded data should never be shared with the study sponsor, steering committee, 219 
investigators, or other study personnel that are involved with potential protocol changes or whom 220 
have contact with investigators, unless the DMC is recommending premature termination, a 221 
position that is in agreement with regulatory standards (Figure 1).2;3  Even with strict data 222 
confidentiality procedures in place, release of unblinded interim data for any purpose (e.g., 223 
planning of phase 3, regulatory submissions, business purposes) can have detrimental and 224 
irrecoverable effects on the integrity of an ongoing trial (e.g., naltrexone/buproprion).25  While 225 
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representation of government sponsors, including project officers and other administrative staff, 226 
during DMC meetings sometimes occurs,24 the authors of this paper discourage such 227 
involvement since the government sponsor’s role is to select centers, monitor progress, and 228 
financially support a clinical trial.  Minimally, unblinded staff should not participate in 229 
discussions or decisions to modify the protocol or be in a position to directly or indirectly, 230 
knowingly or unknowingly, convey information about interim data to others involved in the 231 
study. 232 
 In special circumstances, regulatory agencies may request information from the sponsor 233 
on interim, unblinded data when adverse events of concern have been observed in other studies 234 
of the same drug, drug class, or device.  The DMC may provide this information to regulatory 235 
agencies if the sponsor agrees with the request.  However, regulatory actions taken in response to 236 
the interim data may have major implications on the ability of the study to continue to 237 
completion.  Thus, before undertaking this approach, regulatory agencies should give careful 238 
consideration to all factors, including the strength of the safety signal, quantity of the data, 239 
potential for exposure of the general public (e.g., if the study involves a commercially available 240 
drug), potential for the action to result in premature cessation of the study, and loss of the ability 241 
to achieve a precise answer to the research question of interest.  Rather than request access to 242 
unblinded data, it may be preferable for regulatory agencies to communicate with the sponsor 243 
and request that the DMC undertake closer monitoring for a specific adverse event and allow the 244 
DMC to review the data and make appropriate recommendations regarding study continuation or 245 
termination.  However, this may lead to problems in practice, and regulatory authorities may 246 
decide to take their own, independent, responsibility (e.g., Aliskiren Trial to Minimize Outcomes 247 
in Patients with Heart Failure [ATMOSPHERE]).26;27  Clear communication between the 248 
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regulators, sponsor, steering committee, and DMC can help to ensure optimal decisions are made 249 
that both protect patient safety and trial integrity.  These groups should jointly develop processes 250 
to streamline interactions (e.g., sharing statistical analysis plans rather than unblinded data in 251 
certain circumstances), which might help resolve difficult situations without compromising the 252 
role and responsibilities of either group.26;27 253 
 The DMC acts in an advisory capacity to the executive leadership of the trial and the 254 
study sponsor.  They make recommendations, which the steering committee and/or sponsor must 255 
decide whether or not to follow.  Cases have arisen where steering committees or sponsors chose 256 
not to follow the recommendation of the DMC.28  Likewise, cases have arisen where sponsors 257 
have chosen to release information without involving the DMC (e.g., RECORD, SEAS, 258 
naltrexone/buproprion).22;23;25;29  The DMC charter should describe the course of action that will 259 
be taken in the case of such disagreements (e.g., clear reporting structure to delineate which party 260 
has final decision-making capabilities, processes that will be implemented to resolve 261 
disagreements and achieve consensus such as use of a third-party expert panel to act as 262 
arbitrator). 263 
 264 
IMPORTANCE OF AN EXPERIENCED DATA MONITORING COMMITTEE 265 
 The need for an experienced DMC, particularly the committee chair, has been 266 
underscored by other authors4;17 and regulatory guidance documents.2;3  DMCs should ideally 267 
comprise 3-5 members, including ideally a specialized statistician with experience in 268 
cardiovascular clinical trials and physicians who have clinical training and experience in the field 269 
relevant to the specific study, which might extend beyond the immediate disease state of interest 270 
to other fields (e.g., hepatology, nephrology, neurology, oncology) if there is pre-existing 271 
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concern about specific adverse events or toxicities.  The data center statistician is a non-voting 272 
contributor who should have pertinent experience to construct reports, may maintain minutes, 273 
and will ensure confidentiality of interim data and DMC proceedings.17 274 
 Prior participation in steering committees is desirable preparation for individuals 275 
interesting in serving on a DMC.  Important knowledge is generated through this experience 276 
regarding clinical trial protocol design, study execution and operations, and DMC interactions 277 
that cannot be obtained through seminars, training modules, or reading textbooks or journal 278 
articles on the topic.30 279 
 The need to prepare more individuals for DMC service has been acknowledged (Table 280 
2).4;17;30;31  Membership on a DMC involves reviewing data and making decisions that can be 281 
highly nuanced, concepts which are challenging to convey in didactic type training programs.30  282 
Mentoring programs are one mechanism that could be implemented to provide opportunity for 283 
individuals to participate as non-voting DMC members, alongside experienced DMC members, 284 
to gain the skills required for independent DMC service.  These programs should be extended to 285 
individuals at any career stage.  Targeting early career individuals will provide an opportunity to 286 
realize many years of qualified service for the training investment.  However, late career 287 
individuals represent a valuable resource in terms of clinical and research experience, and may 288 
have less competing responsibilities than early or mid-career investigators.  Sharing DMC 289 
experiences after a trial has concluded through publications7;28;32-34 or other avenues of 290 
dissemination (e.g., supplementary material available with the primary publication, postings on 291 
clinical trial registry database websites) is also encouraged as a means to educate current and 292 
future DMC members and to achieve transparency in the DMC process.  The substantial 293 
contribution that DMCs often make to clinical trials deserves greater recognition, which might 294 
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include being a co-author on papers of study design or primary results, although the potential for 295 
introduction of academic or intellectual bias should be considered. 296 
 297 
ROLE OF THE HEART FAILURE ASSOCIATION AND EUROPEAN HEART 298 
AGENCY 299 
 A key objective of the HFA workshop was to identify areas where HFA, ESC constituent 300 
bodies, and the EHA could contribute to strengthening the utilization of DMCs in cardiovascular 301 
and metabolic clinical trials.  Several areas of potential involvement were identified and will be 302 
further explored and developed by the leadership of these organizations. 303 
 304 
Develop Registry of Data Monitoring Committee Members 305 
 The importance of access to experienced DMC members was a recurring theme raised 306 
during the workshop.  DMC members may be selected on the basis of recommendations from the 307 
steering committee or industry sponsor, but smaller companies or newcomers to the field may 308 
have less knowledge about suitable individuals for DMC service or may lack access to them.  309 
The HFA in collaboration with other ESC constituent bodies (i.e., the Clinical Trials Unit of the 310 
ESC) could create a registry of potential DMC members, including information on past steering 311 
or DMC committee experience and unique expertise they may have in specific disease states or 312 
novel therapeutics.  This would be a valuable resource for Steering Committees and Sponsors, 313 
while also serving to enhance the independence of the DMC since potential members would be 314 
first identified by querying the HFA DMC registry rather than by direct nomination from the 315 
sponsor or steering committee. 316 
 317 
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Advisory Body for Data Monitoring Committees 318 
 Managing conflicts of interest was also emphasized during the workshop as a concern for 319 
modern DMCs.  Conflict of interest information would also be maintained in the registry, and 320 
individuals with conflicts that could not be adequately managed (according to clearly pre-defined 321 
criteria) would be excluded from selection.  For individuals where potential, but manageable, 322 
conflicts were present, the HFA or other relevant ESC constituent bodies could advise steps to 323 
further mitigate the conflict (e.g., discontinue consultant or advisory activities during the course 324 
of the trial).  Finally, HFA or other relevant ESC constituent bodies could lobby sponsors to 325 
provide indemnification with language that protects DMC members from liability and ensures 326 
individual legal counsel will be provided in the event it is needed. 327 
 328 
Develop Training Modules and Facilitate Mentorship Programs 329 
 The suggested DMC registry would also provide infrastructure to match investigators 330 
interested in gaining DMC experience with seasoned DMC members willing to provide 331 
mentorship opportunities.  The mentorship program would combine web-based training modules 332 
with real-life, hands-on experience within a DMC (Table 2).  Trainees would be non-voting 333 
members of the DMC and would gain exposure to all aspects of the DMC process, including 334 
developing a charter, regulatory requirements and expectations for DMCs, reviewing DMC 335 
reports, participating in open and closed DMC sessions, and exposure to communication 336 
pathways between the DMC, sponsor, steering committee, investigators, and regulatory bodies.  337 
The HFA encourages publication of DMC proceedings after completion of those trials where 338 
“lessons learned” would be of value for future DMCs.  HFA, and more broadly ESC, may be 339 
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positioned to facilitate the transparent reporting and public dissemination of this information 340 
through its journal, website, and annual meeting. 341 
 342 
CONCLUSION 343 
 Data monitoring committees play a vital role in protecting human subjects enrolled in 344 
clinical trials, and they instill confidence that the integrity of the trial is intact and the data are 345 
reliable.  The increasingly widespread use of DMCs is accompanied by concerns related to their 346 
independence, conflicts of interest, liability protection, and a lack of qualified individuals for 347 
DMC service.  The topic of DMCs is often discussed in the literature and academic circles, but 348 
few efforts have been adopted to address these challenges.  During the workshop, the HFA 349 
suggested a core set of activities that might be further developed and ultimately implemented to 350 
impact these areas.  The HFA will continue to advise stakeholders in cardiovascular and 351 
cardiometabolic clinical research to promote the integration of independent DMCs in clinical 352 
trials where needed, protect the interests of those serving as DMC members, and cultivate highly 353 
skilled individuals for DMC service. 354 
  355 
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Figure Legends  356 
Figure 1.  Ideal Communication Pathways for Unblinded Data 357 
Figure represents a “firewall” around the DMC (denoted by thicker border), where one-way 358 
input to the DMC can be provided by regulatory authorities or external DMCs, usually with the 359 
knowledge or approval of the steering committee or sponsor.  One-way output of unblinded data 360 
to the steering committee or sponsor only occurs when premature termination is recommended, 361 
although partial flow of unblinded information may occur between a small group of people 362 
within the steering committee or sponsor in an adaptive design.  The only two-way 363 
communication of blinded data occurs between the DMC and the data center statistician. 364 
*Regulatory bodies may request (with the knowledge/approval of the steering committee or 365 
sponsor) that the DMC monitor specific events if concerns emerge from external trials or data. 366 
†Other DMCs may suggest specific events for monitoring if concerns emerge from ongoing 367 
external trials (with the knowledge/approval of the steering committee or sponsor). 368 
‡Blinded data may be communicated between the DMC and steering committee and/or sponsor 369 
when the DMC has concerns about issues that affect the quality of the study (e.g., concerns about 370 
data integrity, timeliness of reporting adverse events, concerns about the nature of the patients 371 
enrolled) 372 
 373 
ARO, academic research organization; CRO, contract research organization; DMC, data 374 
monitoring committee; EC, ethics committee; IRB, institutional review board 375 
  376 
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 Table 1.  Overview of DMC Monitoring Decisions  
Decision Considerations Examples of studies (not intended to be 
comprehensive) 
Stopping for harm11;28  Evidence of harm that creates an 
unfavorable balance between risks and 
potential benefits 
 Review interim data more frequently 
 For known or suspected safety issues, 
stopping boundaries may be defined; 
often less stringent than applied when 
stopping for benefit or futility 
 Safety is multi-factorial and less 
amenable to statistical planning.  
Unexpected safety signals need to be 
interpreted in the context of 
multiplicity, biologic plausibility, 
 ILLUMINATE 
 PALLUS 
 MOXCON 
 CAST 
 PROMISE 
 HERS 
 ALLHAT 
 TRACER 
Table 1.  Overview of DMC Monitoring Decisions (continued) 
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Decision Considerations Examples of studies (not intended to be 
comprehensive) 
external data, and the anticipated 
benefit. 
Stopping for benefit6-11  Should be based on proof beyond a 
reasonable doubt that a treatment effect 
is adequately robust to allow a 
benefit:risk assessment sufficient to 
impact clinical practice and regulatory 
decision-making for pivotal trials 
 Pre-specified statistical stopping 
guidelines should be more stringent 
early in the trial when the number of 
events is likely to be small 
 Stopping for benefit should not be 
considered until at least one-half of the 
 ASCOT 
 CIBIS-II 
 MERIT-HF 
 COPERNICUS 
 RALES 
 A-HeFT 
 EMPHASIS 
 MADIT 
 MADIT II 
 MADIT-CRT 
 COMPANION 
 PARADIGM-HF 
Table 1.  Overview of DMC Monitoring Decisions (continued) 
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Decision Considerations Examples of studies (not intended to be 
comprehensive) 
patients have been enrolled or one-half 
of the expected events have 
accumulated 
 Physician’s Health Study 
 DCCT 
Stopping for futility11  Stopping for futility should not be 
considered until at least one-half of the 
patients have been enrolled or one-half 
of the expected events have 
accumulated 
 Should consider potential for loss of 
information on clinically relevant 
secondary endpoints, safety, a delayed 
treatment effect, definitive evidence of 
neutrality, or other important 
knowledge that may be generated by 
 PERFORM 
 CONSENSUS II (stopped for futility + 
harm in other endpoints) 
 ALTITUDE (stopped for futility + 
harm in other endpoints) 
 EchoCRT 
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Decision Considerations Examples of studies (not intended to be 
comprehensive) 
the trial 
 Predictive and conditional power are 
useful concepts when considering 
futility 
ALLHAT = Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial; ALTITUDE = Aliskiren Trial in Type 2 
Diabetes Using Cardiorenal Endpoints; CAST = Cardiac Arrhythmia Suppression Trial; DCCT = Diabetes Control and Complication 
Trial; EchoCRT = Echocardiography Guided Cardiac Resynchronization Therapy; HERS = Heart and Estrogen/Progestin 
Replacement Trial; ILLUMINATE = Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events; 
MERIT-HF = Metoprolol CR/XL Randomized Intervention Trial in Chronic Heart Failure; MOXCON = Moxonidine Congestive 
Heart Failure Trial; PALLUS = Permanent Atrial Fibrillation Outcome Study Using Dronedarone on Top of Standard Therapy); 
PERFORM = Prevention of Cerebrovascular and Cardiovascular Events of Ischemic Origin with Terutroban in Patients with a History 
of Ischemic Stroke or Transient Ischemic Attack;  PROMISE = Prospective Randomized Milrinone Survival Evaluation; RALES = 
Randomized Aldactone Evaluation Study; TRACER = Thrombin Receptor Antagonist for Clinical Event Reduction in Acute 
Coronary Syndrome  
 Table 2.  Methods of Training Future DMC Members 
 Type of Training 
 Web-based Didactic Training Modules Training Workshops (1-2 day) Hands-on Training 
Content  Review of regulatory guidance 
involving DMCs 
 Discussion of charter and what should 
be included 
 Introduction to contractual agreements 
and indemnification considerations 
 Introduction to viewing and 
interpreting sample interim data reports 
 Methods and processes to maintain 
appropriate firewalls between DMC 
and other study personnel 
 Presentation of case examples 
 Presentation of case studies 
from past real-life DMC 
experiences and interactive 
discussion about possible 
actions, DMC decision 
making and implications 
 Basic training on statistical 
issues including stopping 
rules and analysis of safety 
data 
 Interpretation of data reports 
 Sample exercises for writing a 
DMC charter 
 Assign trainee to a DMC as non-
voting DMC member 
 Partner trainee with experienced 
DMC member, provide mentorship 
 Participate in all aspects of DMC 
(e.g., drafting charter, reviewing 
contracts, negotiating 
indemnification, review of protocol 
and analysis plan, review of draft 
data report, review of actual data 
reports, participation in all 
meetings, including sponsor or 
steering committee interactions) 
 
